<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">702422</article-id><article-id pub-id-type="doi">10.26442/00403660.2026.05.203607</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Cutaneous manifestations of systemic lupus erythematosus and coexisting dermatologic conditions</article-title><trans-title-group xml:lang="ru"><trans-title>Поражение кожи при системной красной волчанке и сопутствующая дерматологическая патология</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1318-1894</contrib-id><name-alternatives><name xml:lang="en"><surname>Shumilova</surname><given-names>Anastasiia A.</given-names></name><name xml:lang="ru"><surname>Шумилова</surname><given-names>Анастасия Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>мл. науч. сотр. лаб. тромбовоспаления, врач-ревматолог</p></bio><email>dr.anashumilova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6399-8766</contrib-id><name-alternatives><name xml:lang="en"><surname>Travkina</surname><given-names>Ekaterina I.</given-names></name><name xml:lang="ru"><surname>Травкина</surname><given-names>Екатерина Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>врач-дерматовенеролог</p></bio><email>dr.anashumilova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0634-5627</contrib-id><name-alternatives><name xml:lang="en"><surname>Sholkina</surname><given-names>Polina A.</given-names></name><name xml:lang="ru"><surname>Шолкина</surname><given-names>Полина Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>мл. науч. сотр. лаб. тромбовоспаления, врач-ревматолог</p></bio><email>dr.anashumilova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3552-2522</contrib-id><name-alternatives><name xml:lang="en"><surname>Reshetnyak</surname><given-names>Tatiana M.</given-names></name><name xml:lang="ru"><surname>Решетняк</surname><given-names>Татьяна Магомедалиевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. лаб. тромбовоспаления, проф. каф. ревматологии</p></bio><email>dr.anashumilova@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Nasonova Research Institute of Rheumatology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» Минобрнауки России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-06-13" publication-format="electronic"><day>13</day><month>06</month><year>2026</year></pub-date><volume>98</volume><issue>5</issue><issue-title xml:lang="en">Issues of rheumatology</issue-title><issue-title xml:lang="ru">Вопросы ревматологии</issue-title><fpage>299</fpage><lpage>305</lpage><history><date date-type="received" iso-8601-date="2026-02-09"><day>09</day><month>02</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-02-20"><day>20</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/702422">https://ter-arkhiv.ru/0040-3660/article/view/702422</self-uri><abstract xml:lang="en"><p><bold>Aim.</bold> To analyze the clinical heterogeneity of cutaneous manifestations in systemic lupus erythematosus (SLE) and the features of coexisting dermatologic conditions in these patients.</p> <p><bold>Materials and methods. </bold>The single-center cross-sectional study included 210 patients with SLE followed at Nasonova Research Institute of Rheumatology. Clinical, laboratory, and instrumental parameters were assessed, including disease activity (SLEDAI-2K [Systemic Lupus Erythematosus Disease Activity Index 2000], SLE-DAS [Systemic Lupus Erythematosus Disease Activity Score]), organ damage (Damage Index of SLICC/ACR [Systemic Lupus International Collaborating Clinics / American College of Rheumatology]), and cutaneous manifestations using the CLASI (Cutaneous Lupus Disease Area and Severity Index), R-CLASI (Revised Cutaneous Lupus Erythematosus Disease Areas and Severity Index), and the mucocutaneous domain of Easy-BILAG (Easy British Isles Lupus Assessment Group). Coexisting dermatologic conditions and skin changes not directly related to SLE activity were additionally analyzed.</p> <p><bold>Results. </bold>Cutaneous and mucosal involvement was observed in 85% of patients during the disease course and represented one of the most frequent manifestations at SLE onset. At study inclusion, active mucocutaneous manifestations were present in 50% of patients. Cutaneous involvement was characterized by marked clinical heterogeneity and a high prevalence of overlapping phenotypes, including acute and chronic cutaneous lupus, mucosal lesions, and non-scarring alopecia. Active cutaneous involvement was associated with serositis and hemolytic anemia. Coexisting dermatologic conditions, including treatment-related skin complications, were identified in 70% of patients.</p> <p><bold>Conclusion. </bold>Cutaneous and mucosal manifestations in SLE constitute a complex, multicomponent disease phenotype reflecting both systemic inflammatory activity and processes of chronicity and damage accumulation. The high prevalence of overlapping cutaneous phenotypes and coexisting dermatologic conditions underscores the need for comprehensive skin assessment and a multidisciplinary approach to the management of patients with SLE.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Проанализировать клиническое разнообразие кожных проявлений системной красной волчанки (СКВ) и их сочетание с сопутствующей дерматологической патологией.</p> <p><bold>Материалы и методы.</bold> В одноцентровое одномоментное исследование включены 210 пациентов с СКВ, наблюдавшихся в ФГБНУ «НИИР им. В.А. Насоновой». Оценивали клинические, лабораторные и инструментальные показатели, активность заболевания (SLEDAI-2K [Systemic Lupus Erythematosus Disease Activity Index 2000] – индекс активности СКВ в модификации 2000 г., SLE-DAS [Systemic Lupus Erythematosus Disease Activity Score] – счет активности СКВ), органное повреждение (индекс повреждения Международной группы сотрудничающих клиник по системной красной волчанке / Американской коллегии ревматологов [Systemic Lupus International Collaborating Clinics / American College of Rheumatology – SLICC/ACR]), кожные проявления с использованием индексов CLASI (Cutaneous Lupus Disease Area and Severity Index – индекс площади и тяжести кожной волчанки), R-CLASI (Revised Cutaneous Lupus Erythematosus Disease Areas and Severity Index – модифицированный индекс площади и тяжести кожной волчанки) и кожно-слизистого домена Easy-BILAG (Easy British Isles Lupus Assessment Group – облегченная группа оценки волчанки на Британских островах). Дополнительно анализировали сопутствующие дерматологические заболевания и кожные изменения, не связанные напрямую с активностью СКВ.</p> <p><bold>Результаты. </bold>Поражение кожи и слизистых оболочек выявлено у 85% пациентов за период заболевания, что являлось одним из частых проявлений дебюта СКВ. У 50% пациентов на момент включения обнаружена активная кожно-слизистая симптоматика. Кожные проявления характеризовались выраженной гетерогенностью и высокой частотой сочетанных фенотипов, включая острые и хронические формы кожной волчанки, поражение слизистых оболочек и нерубцовую алопецию. Активное кожное поражение ассоциировалось с серозитом и гемолитической анемией. У 70% пациентов выявлена сопутствующая дерматологическая патология, включая кожные осложнения терапии.</p> <p><bold>Заключение. </bold>Кожные и слизистые проявления СКВ формируют сложный, многокомпонентный фенотип заболевания, отражающий как активность системного воспаления, так и процессы хронизации, накопления повреждения. Высокая частота сочетанных форм кожной волчанки и сопутствующей дерматологической патологии подчеркивает необходимость комплексной оценки кожного синдрома и междисциплинарного подхода к ведению таких пациентов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>systemic lupus erythematosus</kwd><kwd>skin lesions</kwd><kwd>dermatological diseases</kwd><kwd>skin lupus</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>системная красная волчанка</kwd><kwd>поражение кожи</kwd><kwd>дерматологические заболевания</kwd><kwd>красная кожная волчанка</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The article was prepared within the framework of the research project of Nasonova Research Institute of Rheumatology No. 125020501434-1.</funding-statement><funding-statement xml:lang="ru">Статья подготовлена в рамках темы ФГБНУ «НИИР им. В.А. Насоновой» №125020501434-1.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Stull C, Sprow G, Werth VP. Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist. J Rheumatol. 2023;50(1):27-35. DOI:10.3899/jrheum.220089</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Niebel D, de Vos L, Fetter T, et al. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions. Am J Clin Dermatol. 2023;24(4):521-40. DOI:10.1007/s40257-023-00774-8</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;64(5):849-58. DOI:10.1016/j.jaad.2010.02.008</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Joseph A, Prasad S, Hynan LS, et al. Differences in quality of life in patients with cutaneous lupus erythematosus with varying income levels. Lupus. 2021;30(6):972-80. DOI:10.1177/0961203321999724</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471-5. DOI:10.1016/s0190-9622(81)80261-7</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018;153(2):216-29. DOI:10.23736/S0392-0488.18.05929-1</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Brahmanti H, Wahono CS, Pratama MZ, et al. Association of the Spectrum of Cutaneous Lupus Erythematosus with Disease Activity and Systemic Manifestations in Patients with Systemic Lupus Erythematosus. Mediterr J Rheumatol. 2024;35(1):143-9. DOI:10.31138/mjr.200423.aos</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hannon CW, McCourt C, Lima HC, et al. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;3(3):CD007478. DOI:10.1002/14651858.CD007478.pub2</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Errichetti E, Lallas A, De Marchi G, et al. Dermoscopy in the differential diagnosis between malar rash of systemic lupus erythematosus and erythematotelangiectatic rosacea: an observational study. Lupus. 2019;28(13):1583-8. DOI:10.1177/0961203319882493</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dessinioti C, Antoniou C. The "red face": Not always rosacea. Clin Dermatol. 2017;35(2):201-6. DOI:10.1016/j.clindermatol.2016.10.015</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mokhtari F, Ganjei Z. A rare form of discoid lupus erythematosus as a rosacea and angiofibroma: A case report. Clin Case Rep. 2020;8(1):155-8. DOI:10.1002/ccr3.2611</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-91.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 2019;78(3):365-71. DOI:10.1136/annrheumdis-2018-214502</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Jesus D, Larosa M, Henriques C, et al. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis. 2021;80(12):1568-74. DOI:10.1136/annrheumdis-2021-220363</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Carter LM, Gordon C, Yee CS, et al. Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology (Oxford). 2022;61(10):4006-15. DOI:10.1093/rheumatology/keab883</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Шумилова А.А., Чельдиева Ф.А., Нурбаева К.С., и др. Адаптация русскоязычной версии индекса активности системной красной волчанки EASY-BILAG. Современная ревматология. 2023;17(5):107-11 [Shumilova AA, Cheldieva FA, Nurbaeva KS, et al. Adaptation of the Russian version of the activity index of systemic lupus erythematosus EASY-BILAG. Modern Rheumatology Journal. 2023;17(5):107-11 (in Russian)]. DOI:10.14412/1996-7012-2023-5-107-111</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889-94. DOI:10.1111/j.0022-202X.2005.23889.x</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010;163(1):83-92. DOI:10.1111/j.1365-2133.2010.09799.x</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Шумилова А.А., Чельдиева Ф.А., Нурбаева К.С., и др. Индексы активности поражения и повреждения кожи у пациентов с системной красной волчанкой – CLASI и R-CLASI. Научно-практическая ревматология. 2024;62(2):203-15 [Shumilova АА, Cheldieva FA, Nurbaeva KS, et al. Indexes of skin activity and damage in patients with systemic lupus erythematosus – CLASI and R-CLASI. Rheumatology Science and Practice. 2024;62(2):203-15 (in Russian)]. DOI:10.47360/1995-4484-2024-203-215</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-9. DOI:10.1002/art.1780390303</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Sayhi S, Achour TB, Mezri S, et al. Clinical Features of Systemic Lupus Erythematosus in Tunisian Males. Curr Rheumatol Rev. 2020;16(2):139-42. DOI:10.2174/1573397115666190916142945</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Chanprapaph K, Tankunakorn J, Suchonwanit P, Rutnin S. Dermatologic Manifestations, Histologic Features and Disease Progression among Cutaneous Lupus Erythematosus Subtypes: A Prospective Observational Study in Asians. Dermatol Ther (Heidelb). 2021;11(1):131-47. DOI:10.1007/s13555-020-00471-y</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Koch K, Tikly M. Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus. Lupus. 2019;28(8):1021-6. DOI:10.1177/0961203319856091</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Zhou W, Wu H, Zhao M, Lu Q. New insights into the progression from cutaneous lupus to systemic lupus erythematosus. Expert Rev Clin Immunol. 2020;16(8):829-37. DOI:10.1080/1744666X.2020.1805316</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>George RT, Murthy SC, Raghuveer C, Degulamadi VH. Colocalisation of subacute cutaneous lupus erythematosus and vitiligo in a woman with thyroid autoantibodies: An intriguing association. Indian J Dermatol Venereol Leprol. 2022;88(2):219-21. DOI:10.25259/IJDVL_351_2021</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Cosentino M, Martire MV, García L, García MA. Cutaneous manifestations in patients with systemic lupus erythematosus: Forms at the beginning of the disease and during follow-up. Retrospective analysis. Reumatol Clin (Engl Ed). 2023;19(6):293-8. DOI:10.1016/j.reumae.2022.11.008</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>McNamara K, Hughes OB, Strowd LC. Cutaneous drug eruptions including serum sickness-like reaction, symmetrical drug-related intertriginous and flexural exanthema, and drug-induced lupus. Clin Dermatol. 2020;38(6):641-7. DOI:10.1016/j.clindermatol.2020.06.013</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Yamamoto T. Psoriasis and Connective Tissue Diseases. Int J Mol Sci. 2020;21(16):5803. DOI:10.3390/ijms21165803</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Esquivel-Valerio JA, Cardenas-de la Garza JA, Arvizu-Rivera RI, Galarza-Delgado DA. Disseminated anetoderma associated with antiphospholipid antibodies. Clin Rheumatol. 2020;39(12):3887-8. DOI:10.1007/s10067-020-05321-y</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Martín Carmona J, Gómez Moyano E, Ayala Blanca M, Martínez Pilar L. Anetoderma associated with antiphospholipid syndrome. Med Clin (Barc). 2020;154(7):288. DOI:10.1016/j.medcli.2019.04.036</mixed-citation></ref></ref-list></back></article>
